BridgeBio Oncology Therapeutics, Inc (BBOT) vs Ocugen, Inc. (OCGN)

BridgeBio Oncology Therapeutics, Inc and Ocugen, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Ocugen, Inc. are of similar size ($339.1M and $319.9M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −1,786.3%) and the lower return on invested capital (−127.7% vs 0.00%). Across the 12 metrics below, Ocugen, Inc. leads on 7 and BridgeBio Oncology Therapeutics, Inc on 5.

Valuation

Metric BBOT OCGN Biotechnology median
P/E n/m n/m 7.88
P/S n/m 75.43 11.47
P/B 0.98 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 53.96 10.73
Earnings yield (69.87%) (25.49%) (28.84%)
Free cash flow yield (47.93%) (17.66%) (23.03%)

Profitability

Metric BBOT OCGN Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (1,504.43%) 0.00%
Net margin 0.00% (1,786.27%) 0.00%
Free cash flow margin 0.00% (1,332.36%) 0.00%
Return on equity (252.10%) 1,211.66% (57.72%)
Return on assets (96.69%) (92.03%) (49.22%)
Return on invested capital (127.66%) 0.00% 0.00%

Growth

Metric BBOT OCGN Biotechnology median
Revenue growth (TTM) — (3.66%) 5.64%
EPS growth (last fiscal year) 99.93% (15.00%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT OCGN Biotechnology median
Debt to equity 0.00 (0.11) 0.00
Current ratio 4.69 0.80 4.73
Net debt to EBITDA 2.93 (0.17) 0.96

Dividend

Metric BBOT OCGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric BBOT OCGN Biotechnology median
Market cap 319.90m 339.11m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack